Exposure/treatment to an investigational (new chemical entity) or marketed drug or biologic within 30 days preceding the first dose administration, or five half-lives of that investigational drug or biologic, if known (whichever is longer). 
Donation blood or serum within 8 weeks before the first dose administration to a blood bank or blood donation center. 
History of alcohol or drug abuse (as defined by the current version of the DSM) within 2 years before the first dose administration, or positive alcohol or drug screen. 
Vaccination within 30 days prior to the first dose administration or has plans to receive a vaccination during the course of the study (including the follow phone call on Day 105).       
    

NCT02934269_exc_T3
Procedure
Donation blood
NCT02934269_exc_T5
Procedure
Donation serum
NCT02934269_exc_T7
Temporal
within 8 weeks before
NCT02934269_exc_T8
Reference_point
first dose administration
NCT02934269_exc_T9
Condition
alcohol abuse
NCT02934269_exc_T10
Condition
drug abuse
NCT02934269_exc_T11
Observation
History
NCT02934269_exc_T12
Procedure
current version of the DSM
NCT02934269_exc_T13
Temporal
within 2 years before
NCT02934269_exc_T14
Reference_point
the first dose administration
NCT02934269_exc_T15
Measurement
alcohol screen
NCT02934269_exc_T16
Measurement
drug screen
NCT02934269_exc_T17
Value
positive
NCT02934269_exc_T18
Scope
alcohol or drug abuse
NCT02934269_exc_T19
Procedure
Vaccination
NCT02934269_exc_T20
Temporal
within 30 days prior
NCT02934269_exc_T21
Reference_point
the first dose administration
NCT02934269_exc_T22
Observation
plans
NCT02934269_exc_T24
Procedure
vaccination
NCT02934269_exc_T25
Temporal
during the course
NCT02934269_exc_T26
Reference_point
study